Eflornithine
Anaplastic Astrocytoma (AA3 / Grade 3 Glioma)
Phase 3Active
Key Facts
Indication
Anaplastic Astrocytoma (AA3 / Grade 3 Glioma)
Phase
Phase 3
Status
Active
Company
About Orbus Therapeutics
Orbus Therapeutics is a private, pre-revenue biotech founded in 2004 and headquartered in Palo Alto, California. The company's sole clinical asset is eflornithine, which recently completed its pivotal Phase 3 STELLAR trial in 2024 for the treatment of anaplastic astrocytoma, a rare brain tumor. With a seasoned leadership team experienced in CNS and oncology drug development, Orbus is positioned to potentially bring a new treatment option to a patient population with very limited effective therapies. The company's near-term future hinges on the results and regulatory review of the STELLAR study.
View full company profile